References
- ZhengRZengHZuoTLung cancer incidence and mortality in China, 2011Thorac Cancer201671949926816543
- SongZShaoLLinBZhangYSingle-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysisClin Transl Oncol2013151084384823423808
- LevyBSaxenaASchneiderBJSystemic therapy for small cell lung cancerJ Natl Compr Canc Netw201311778078723847216
- LeeCKWuYLDingPNImpact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysisJ Clin Oncol201533171958196525897154
- HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
- ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
- MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
- BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
- ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
- SongZYuXZhangYAltered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinomaLung Cancer20169916617127565935
- SongZYuXChengGZhangYProgrammed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinomaJ Transl Med201614118827342566
- OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
- ThompsonRHGillettMDChevilleJCCostimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetProc Natl Acad Sci U S A200410149171741717915569934
- IshiiHAzumaKKawaharaASignificance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancerJ Thorac Oncol201510342643025384063
- AliHRGlontSEBlowsFMPD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytesAnn Oncol2015261488149325897014
- BaiHWangZChenKInfluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancerJ Clin Oncol201230253077308322826274
- GainorJFSequistLShawATClinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC)J Clin Oncol201533suppl Abstract 8012
- LinCChenXLiMProgrammed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinomaClin Lung Cancer2015165e25e3525801750
- ChenNFangWZhanJUpregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutationJ Thorac Oncol201510691092325658629